Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)vsBeOne Medicines AG (ONC)
LABT
Lakewood-Amedex Biotherapeutics Inc. Common Stock
$0.36
-9.06%
HEALTHCARE · Cap: $985,790
ONC
BeOne Medicines AG
$415.96
-0.96%
HEALTHCARE · Cap: $46.30B
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 13.9% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 70/100 (B-).
LABT
Avoid26
out of 100
Grade: F
ONC
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LABT.
Margin of Safety
+81.0%
Fair Value
$1845.68
Current Price
$415.96
$1429.72 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 33.8% year-over-year
Earnings expanding 212.5% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Strong operational efficiency at 22.2%
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Trading at 8.2x book value
Premium valuation, high expectations priced in
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : LABT
The strongest argument for LABT centers on Price/Book, Debt/Equity.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, EPS Growth, Debt/Equity. Revenue growth of 33.8% demonstrates continued momentum. PEG of 0.82 suggests the stock is reasonably priced for its growth.
Bear Case : LABT
The primary concerns for LABT are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are Price/Book, P/E Ratio, Altman Z-Score. A P/E of 52.2x leaves little room for execution misses.
Key Dynamics to Monitor
LABT profiles as a value stock while ONC is a growth play — different risk/reward profiles.
ONC is growing revenue faster at 33.8% — sustainability is the question.
ONC generates stronger free cash flow (474M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (70/100 vs 26/100) and 33.8% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Lakewood-Amedex Biotherapeutics Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Labtec Inc. (Ticker: LABT) is a forward-thinking biotechnology company dedicated to revolutionizing drug delivery systems and diagnostic solutions. By leveraging cutting-edge technologies and fostering strategic partnerships, Labtec aims to address critical healthcare challenges and improve patient outcomes. With a comprehensive product portfolio and a strong commitment to meeting unmet medical needs, Labtec is well-positioned for substantial growth in the rapidly evolving biotech sector, representing a compelling investment opportunity for institutional investors.
BeOne Medicines AG
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?